In the Specification:

On page 132, line 24 to page 133, line 6, please amend the specification as follows:

3.1. Brief Description of the Drawings

Various aspects of the invention can be understood with reference to the figures described below:

- FIGS. 1a to 1v illustrates various preferred compounds of the invention
- FIG. 2 FIG. 1 illustrates the effect of one week of daily oral gavage treatment on lipoprotein total cholesterol in chow-fed male Sprague-Dawly rats.
- FIG. 3 FIG. 2 illustrates the effect of one week of daily oral gavage treatment on serum lipids in chow-fed male Sprague-Dawly rats;
- FIG. 4 FIG. 3 illustrates the effect of two weeks of daily oral gavage treatment on lipoprotein total cholesterol in chow-fed obese female Zucker rats;
- FIG. 5 FIG. 4 is a table illustrating the effect of two weeks of daily oral gavage treatment using a specific compound of the invention in chow-fed obese female Zucker rats; and
- FIG. 5 is a table illustrating the effect of two weeks of daily oral gavage treatment using a specific compound of the invention on the synthesis of saponified and non-saponified lipids in hepatocyte cells isolated from male Sprague-Dawly rats.